이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Zydus Lifesciences 관리

관리 기준 확인 3/4

Zydus Lifesciences' CEO는 Sharvil Patel, Apr2017 에 임명되었습니다 의 임기는 7.17 년입니다. 총 연간 보상은 ₹ 262.50M, 68.6% 로 구성됩니다. 68.6% 급여 및 31.4% 보너스(회사 주식 및 옵션 포함). 는 ₹ 15.88M 가치에 해당하는 회사 주식의 0.001% 직접 소유합니다. 15.88M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 9.1 년입니다.

주요 정보

Sharvil Patel

최고 경영자

₹300.0m

총 보상

CEO 급여 비율	60.0%
CEO 임기	7.4yrs
CEO 소유권	0.001%
경영진 평균 재임 기간	6.4yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

CEO 보상 분석

Sharvil Patel 의 보수는 Zydus Lifesciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	₹42b
Mar 31 2024	₹300m	₹180m	₹38b
Dec 31 2023	n/a	n/a	₹30b
Sep 30 2023	n/a	n/a	₹28b
Jun 30 2023	n/a	n/a	₹25b
Mar 31 2023	₹263m	₹180m	₹20b
Dec 31 2022	n/a	n/a	₹21b
Sep 30 2022	n/a	n/a	₹20b
Jun 30 2022	n/a	n/a	₹22b
Mar 31 2022	₹200m	₹180m	₹22b
Dec 31 2021	n/a	n/a	₹23b
Sep 30 2021	n/a	n/a	₹23b
Jun 30 2021	n/a	n/a	₹23b
Mar 31 2021	₹263m	₹180m	₹22b
Dec 31 2020	n/a	n/a	₹18b
Sep 30 2020	n/a	n/a	₹17b
Jun 30 2020	n/a	n/a	₹13b
Mar 31 2020	₹250m	₹247m	₹12b
Dec 31 2019	n/a	n/a	₹12b
Sep 30 2019	n/a	n/a	₹14b
Jun 30 2019	n/a	n/a	₹17b
Mar 31 2019	₹250m	₹248m	₹18b
Dec 31 2018	n/a	n/a	₹20b
Sep 30 2018	n/a	n/a	₹20b
Jun 30 2018	n/a	n/a	₹21b
Mar 31 2018	₹250m	₹248m	₹18b

보상 대 시장: Sharvil 의 총 보상 ($USD 3.14M )은 Indian 시장( $USD 974.14K ).

보상과 수익: Sharvil 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sharvil Patel (45 yo)

7.4yrs

테뉴어

₹300,000,000

보상

Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sharvil Patel	MD & Executive Director	7.4yrs	₹300.00m	0.0015% ₹ 15.9m
Ganesh Nayak	COO & Executive Director	7.2yrs	₹140.00m	0.035% ₹ 374.6m
Punit Patel	President & CEO of America	less than a year	데이터 없음	데이터 없음
Nitinkumar Parekh	Chief Financial Officer	no data	₹54.31m	데이터 없음
Arvind Bothra	Head of Investor Relations	no data	데이터 없음	데이터 없음
Dhaval Soni	Company Secretary & Compliance Officer	5.6yrs	₹2.09m	데이터 없음

6.4yrs

평균 재임 기간

경험이 풍부한 관리: ZYDUSLIFE 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sharvil Patel	MD & Executive Director	27.1yrs	₹300.00m	0.0015% ₹ 15.9m
Ganesh Nayak	COO & Executive Director	7.2yrs	₹140.00m	0.035% ₹ 374.6m
Pankaj Patel	Non-Executive Chairman	29.3yrs	₹1.20m	74.98% ₹ 811.7b
Apurva Diwanji	Independent Director	8.3yrs	₹4.00m	데이터 없음
Mukeshbhai Patel	Non-Executive Non-Independent Director	27.1yrs	₹4.00m	0.0012% ₹ 12.6m
Bhadresh Shah	Independent Non-Executive Director	5.8yrs	₹4.10m	데이터 없음
Akhil Monappa	Independent Director	1.8yrs	₹3.50m	데이터 없음
Upasana Konidela	Independent Director	1.8yrs	₹3.50m	데이터 없음
Shelina Parikh	Independent Director	less than a year	데이터 없음	0.00044% ₹ 4.8m

7.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: ZYDUSLIFE 의 이사회는 경험(평균 재직 기간 9.1 년)으로 간주됩니다.

Zydus Lifesciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Insider recently sold ₹833k worth of stock

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023